Mamta Parikh,Primo N Lara
Mamta Parikh
A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer [0.03%]
免疫检查点抑制剂治疗非透明细胞肾癌的系统评价
Ana Filipa Palma Dos Reis,Diana Simão,Thomas Odeny et al.
Ana Filipa Palma Dos Reis et al.
Background: Immune checkpoint inhibitors (ICI) have emerged as active therapies in the management of advanced RCC. While multiple studies have shown clinical activity of ICIs in clear cell histologies, the evidence to sup...
Marc Dall&#x;Era,Primo N Lara Jr
Marc Dall&#x;Era
Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States [0.03%]
美国转移性肾细胞癌老年患者的口服抗癌药物的实际使用及相关的花费分析
Lauren E Wilson,Lisa Spees,Jessica Pritchard et al.
Lauren E Wilson et al.
Background: Substantial racial and socioeconomic disparities in metastatic RCC (mRCC) have persisted following the introduction of targeted oral anticancer agents (OAAs). The relationship between patient characteristics a...
A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma [0.03%]
晚期非透明细胞肾细胞癌系统治疗选择的系统性评价
Chelsea K Osterman,Tracy L Rose
Chelsea K Osterman
Introduction: There have been a number of recent advances in the management of advanced clear cell renal cell carcinoma (ccRCC). However, the majority of these studies excluded patients with non-clear cell RCC (nccRCC), a...
Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic [0.03%]
COVID-19大流行期间利用twitter平台促进泌尿生殖系统肿瘤防治知识的传播与交流
Sabrina Salgia,Nicholas Salgia,Sweta Prajapati et al.
Sabrina Salgia et al.
Objectives: To better characterize the relay of information about prostate, kidney, and bladder cancer on Twitter in relation to the COVID-19 pandemic. Ma...
Prognostic Value of Histologic Subtype and Treatment Modality for T1a Kidney Cancers [0.03%]
T1a期肾癌的病理亚型和治疗方式的预后价值
Michael Siev,Audrey Renson,Hung-Jui Tan et al.
Michael Siev et al.
Introduction: To evaluate overall survival (OS) of T1a kidney cancers stratified by histologic subtype and curative treatment including partial nephrectomy (PN), percutaneous ablation (PA), and radical nephrectomy (RN). ...
Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma [0.03%]
转移性透明细胞肾细胞癌老年患者初始系统治疗的趋势分析
Chelsea K Osterman,Allison M Deal,Matthew I Milowsky et al.
Chelsea K Osterman et al.
Background: The treatment landscape for metastatic clear cell renal cell carcinoma (mRCC) is rapidly changing. It is unknown how adoption of new types of therapies may differ by patient age. ...
The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice [0.03%]
肾细胞癌的泛组学特征及其对未来临床实践的影响
Jennifer J Huang,James J Hsieh
Jennifer J Huang
Renal cell carcinoma has traditionally been classified based on histological features. Contemporary studies have identified genomic, transcriptomic, epigenomic, and metabolomic signatures that correspond to or even transcend histological su...
Katherine Emilie Rhoades Smith,Mehmet Asim Bilen
Katherine Emilie Rhoades Smith
Papillary renal cell carcinoma (PRCC) is a subtype of renal cell carcinoma (RCC) accounting for approximately 15-20% of cases and further divided into Type 1 and Type 2. Type 1 PRCC tends to have more alterations in the MET tyrosine kinase ...